Compare IND. SWIFT with KILITCH DRUGS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IND. SWIFT vs KILITCH DRUGS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IND. SWIFT KILITCH DRUGS IND. SWIFT/
KILITCH DRUGS
 
P/E (TTM) x -2.5 39.1 - View Chart
P/BV x - 1.9 - View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 IND. SWIFT   KILITCH DRUGS
EQUITY SHARE DATA
    IND. SWIFT
Mar-21
KILITCH DRUGS
Mar-21
IND. SWIFT/
KILITCH DRUGS
5-Yr Chart
Click to enlarge
High Rs5139 3.6%   
Low Rs278 2.4%   
Sales per share (Unadj.) Rs65.744.2 148.6%  
Earnings per share (Unadj.) Rs-5.52.4 -226.4%  
Cash flow per share (Unadj.) Rs0.53.7 14.4%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs-128.481.8 -156.8%  
Shares outstanding (eoy) m54.1615.49 349.6%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.12.5 2.1%   
Avg P/E ratio x-0.644.6 -1.4%  
P/CF ratio (eoy) x6.429.2 21.9%  
Price / Book Value ratio x01.3 -2.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m1841,679 11.0%   
No. of employees `000NANA-   
Total wages/salary Rs m51252 976.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,561685 519.6%  
Other income Rs m15227 570.7%   
Total revenues Rs m3,713712 521.5%   
Gross profit Rs m40253 755.7%  
Depreciation Rs m32720 1,646.7%   
Interest Rs m5229 5,949.6%   
Profit before tax Rs m-29551 -576.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m314 23.9%   
Profit after tax Rs m-29838 -791.5%  
Gross profit margin %11.37.8 145.4%  
Effective tax rate %-1.126.4 -4.1%   
Net profit margin %-8.45.5 -152.3%  
BALANCE SHEET DATA
Current assets Rs m2,652804 330.0%   
Current liabilities Rs m7,062733 963.2%   
Net working cap to sales %-123.910.3 -1,204.1%  
Current ratio x0.41.1 34.3%  
Inventory Days Days153333 46.0%  
Debtors Days Days1,1071,221 90.6%  
Net fixed assets Rs m4,0641,215 334.4%   
Share capital Rs m108155 69.9%   
"Free" reserves Rs m-7,0601,113 -634.4%   
Net worth Rs m-6,9521,268 -548.3%   
Long term debt Rs m6,4420-   
Total assets Rs m6,7162,019 332.6%  
Interest coverage x0.46.8 6.4%   
Debt to equity ratio x-0.90-  
Sales to assets ratio x0.50.3 156.2%   
Return on assets %3.32.3 144.8%  
Return on equity %4.33.0 144.4%  
Return on capital %-44.54.7 -940.4%  
Exports to sales %74.20-   
Imports to sales %5.00-   
Exports (fob) Rs m2,643NA-   
Imports (cif) Rs m176NA-   
Fx inflow Rs m2,682189 1,416.4%   
Fx outflow Rs m26049 534.8%   
Net fx Rs m2,422141 1,721.0%   
CASH FLOW
From Operations Rs m772457 169.2%  
From Investments Rs m-167-376 44.5%  
From Financial Activity Rs m-48316 -2,992.4%  
Net Cashflow Rs m12297 126.1%  

Share Holding

Indian Promoters % 24.1 68.3 35.3%  
Foreign collaborators % 31.5 0.0 -  
Indian inst/Mut Fund % 0.0 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 44.5 31.7 140.4%  
Shareholders   12,424 8,740 142.2%  
Pledged promoter(s) holding % 68.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IND. SWIFT With:   SAKAR HEALTHCARE   PARNAX LAB  JAGSON PHAR  SUVEN PHARMACEUTICALS  ORTIN LABS   



Today's Market

M&M Tractor Sales, Nykaa's Expansion Plan, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note yesterday. Benchmark indices displayed a positive bias yesterday backed by supportive global cues and encouraging macro-economic data.

Related Views on News

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market(Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IND. SWIFT SHARE PRICE


Dec 1, 2021 (Close)

TRACK IND. SWIFT

  • Track your investment in IND. SWIFT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IND. SWIFT - ORCHID PHARMA COMPARISON

COMPARE IND. SWIFT WITH

MARKET STATS